← Back to search

VERTEX PHARMACEUTICALS INCORPORATED

VRTX · NASDAQ

Pharmaceutical Preparation Manufacturing

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

ESG Scores

Overall ESG
6.1
Environmental
5.4
Social
3.9
Governance
6.3

Public ESG Grades

Overall: BBB (High)
E: AS: BBG: BB

Gender Diversity

Female Directors0.3636%
Female Executives0.36303630363036304%
Women in Workforce0.54%
CEO GenderFemale

Market Data

Price$441.20+5.55 (+1.27%)
Market Cap$112.22B
P/E Ratio28.39
EPS$—
52W High$510.77
52W Low$362.50
Beta0.33